Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
View
or print this bulletin in its original format.
Medical Update Memo
November 9, 2009
Summary
The Olympus trial group, including Canadian researchers Drs. Paul O’Connor, Mark Freedman and Jack Antel, report on the use of Rituximab in primary progressive multiple sclerosis. Ann Neurol. 2009 Sep 9;66(4):460-471
Details
Rituximab is a monoclonal antibody which selectively targets CD20, a specific antigen (i.e. protein) present on the surface of B cells, a type of immune cell. This treatment has been proven to be effective in reducing disease activity in relapsing-remitting MS. Since no treatment has been shown to be effective in delaying the progression of primary progressive MS (PPMS), the authors aimed to investigate the efficacy of rituximab in people with PPMS. In this multicentre, double blind, placebo controlled, clinical trial, people were randomised to receive either rituximab or a placebo. The main aim of the study was to investigate whether rituximab could delay the time to confirmed progression compared to placebo. Although the time to confirmed progression was not different between the two groups, some efficacy was observed for people with high inflammatory activity in their MRI and/or people younger than 51 years old.
National Research and Programs
Offert en français.
Disclaimer
The Multiple Sclerosis Society of Canada is an independent, voluntary health
agency and does not approve, endorse or recommend any specific product or therapy,
but provides information to assist individuals in making their own decisions.
Back
to top  |
